-
Aurinia is reverse-merging with Isotechnika to form a publicly traded entity with a simplified ownership of voclosporin, which the newco hopes will enable it to raise the cash needed for a Phase IIb trial in lupus …
Published on 3/4/2013
-
Retiring Shire CEO Angus Russell says the industry needs a new generation of chief executives who understand markets in a way that is fundamentally different from commercially minded CEOs of the past.
Published on 3/4/2013
-
Europe Ltd. Europe's negative numbers Aggregate European sales by 10 innovator pharmas fell $10.1 billion (11%) in 2012 compared to 2011, while U.S. sales dropped $6.2 billion (5%). The U.S. falloff was driven by …
Published on 2/18/2013
-
Pharma companies are starting to shrink their footprints in Europe in the face of pressure on prices and reimbursement. But emerging markets and the U.S. won't lessen the need for new strategies to address shrinking …
Published on 2/18/2013
-
In 2008, Chiasma's new CEO refocused the formulation play on product development to capture more upside from its technology. The strategy has paid off with a deal for its oral somatostatin analog with Roche.
Published on 2/18/2013
-
Merck Serono's Entrepreneur Partnership Program allows the pharma to preserve access to key assets while making cutbacks necessary to improve its fiscal health.
Published on 2/11/2013
-
Aegerion is betting its data will support broad use of hoFH drug Juxtapid lomitapide despite the introduction of Genzyme's Kynamro mipomersen at $59,000-$119,000 less per year.
Published on 2/4/2013
-
NPS believes the $295,000 price tag for Orphan drug Gattex could reduce overall treatment costs. The math may prove to add up only for a subset of cases, but the company does not expect patients to bear the brunt.
Published on 1/14/2013
-
While M&A deals often prove to be disappointing value creation events, Alkermes has been delivering on its goals for business building and valuation after spending $960 million for Elan Drug Technologies.
Published on 12/24/2012
-
The big biotech believes it is equipped to turn deCode's discoveries into compounds with the greatest chance of success as drugs -- something the Icelandic genomics pioneer failed to do.
Published on 12/24/2012
-
Teva's new management expects to achieve sustainable growth by globalizing key functions to change its cost structure, regionalizing its product offerings, and using BD to amass capabilities incrementally.
Published on 12/17/2012
-
Takeda is building out Nycomed's infrastructure in Russia in preparation for expected reimbursement changes that would make the market more able to pay for innovator drugs.
Published on 12/17/2012
-
Teva's puzzle pieces Global Teva The new management at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is pursuing a growth strategy that involves marrying its different product lines in generics and branded …
Published on 12/17/2012
-
Teva's new roadmap Teva looks ahead On Nov. 30, Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) provided detailed non-GAAP guidance on each of its lines of business for the first time. It also reiterated 2012 …
Published on 12/10/2012
-
President and CEO Jeremy Levin and CSO and President of Global R&D Michael Hayden plan to mine Teva's portfolio of generics for new products, while expanding its branded CNS and respiratory pipeline.
Published on 12/10/2012
-
After years of working on cancer trials at a CRO, the founders of Oncoethix are in-licensing and developing novel cancer therapeutics for themselves -- but only after replicating preclinical results.
Published on 12/3/2012
-
Takeda cozied up to Envoy with a venture investment and target collaboration before pulling the trigger on a deal to acquire the biotech for its bacTRAP discovery platform and preclinical CNS pipeline.
Published on 12/3/2012
-
Calling pharma's bluff Top private biotech financings Intarcia Therapeutics Inc. is one of only five private biotechs in the history of the industry to raise over $200 million in a debt and/or equity financing. …
Published on 11/19/2012
-
Celgene's venture model Celgene's equity deals Despite the lack of a venture arm, since 2007 Celgene Corp. (NASDAQ:CELG) has provided venture funding to at least eight companies and done six deals in which it took …
Published on 11/19/2012
-
Even without a corporate VC arm, the big biotech has been an active investor in private biotechs. But PharmAria is the first time it has seeded a newco.
Published on 11/19/2012
-
Rather than accept suboptimal term sheets from pharma, Intarcia raised a huge $210 million private round to get Phase III data for its long-acting GLP-1 diabetes candidate.
Published on 11/19/2012
-
Sanofi's post-launch discount for Zaltrap may address oncologist objections to the colorectal cancer drug's cost, but it may not improve either patient access or physician uptake.
Published on 11/19/2012
-
Vertex says the decline in Incivek sales are due to marketwide factors, but some HCV doctors report that anemia and payer preferences also are playing a role.
Published on 11/12/2012
-
Despite Qsymia's modest early sales, Vivus believes the obesity drug will start to take off in the next six months as physicians begin to see efficacy and the biotech addresses roadblocks to building a market.
Published on 11/12/2012
-
When Alnylam decided to find an Asian partner for its TTR RNAi therapy, Genzyme emerged as the best option due to its Orphan network in Japan and Sanofi's commitment in other emerging Asian markets.
Published on 11/5/2012